Compare Amphastar Pharmaceuticals Inc (AMPH) vs IONQ Inc (IONQ) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

IONQ trades at $42.86, down 4.27% on the day, with a bearish technical signal from moving averages but bullish oscillators. The company reported strong revenue growth with 2025 revenue of $130.02M and a net loss of $510.38M, though profitability is projected for 2026. Recent earnings beats in Q4 2025 and Q1 2026 contrast with a Q3 2025 miss, while analyst consensus is split evenly between Buy and Hold ratings.

Outlook remains speculative with high valuation multiples (P/E 109.9, P/S 72.37) reflecting growth expectations in quantum computing. Key risks include cash burn and competitive pressures, but institutional sentiment is supported by a $73.75 price target and strong liquidity position.